Close Menu

NEW YORK ─ In the early days of the SARS-CoV-2 pandemic, many observers saw substantial commercial and clinical potential for serology tests for the virus.

Yet, despite this initial enthusiasm, these assays have struggled to carve out a significant market, hampered by concerns about test performance and the lack of a clear role in clinical decision-making.

Get the full story with
360Dx Premium

Only $95 for the
first 90 days*

360Dx Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try 360Dx Premium now.

You may already have institutional access!

Check if I qualify.

Already a 360Dx or GenomeWeb Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.